Kardium, the developer of the Globe Pulsed Field System for atrial fibrillation (AF), has raised $250 million in a financing round led by new investors, including Janus Henderson Investors and the Qatar Investment Authority, with participation from existing investors such as T. Rowe Price. This round includes an equity investment from a key strategic investor.
Recent data from the PULSAR study, presented at the 2025 Heart Rhythm Society annual meeting, showed an impressive 78% freedom rate from atrial arrhythmia after one year in paroxysmal AF patients, with no device-related safety events.
The Globe Pulsed Field System features a catheter with a 122-electrode array and advanced software for rapid pulmonary vein isolation, high-definition mapping, and atrial ablation—all of which can be achieved using a single catheter.
How the funding will be used: Kardium’s new funding will help secure regulatory approvals for the Globe System, expand manufacturing capacity, and build a clinical support and commercial team in preparation for its launch later this year. It will also facilitate further clinical research for new applications and indications of the Globe System.
KEY QUOTES:
“We’re thrilled to have secured this transformational financing with a world-class syndicate of investors. This funding enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energized by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation.”
Kevin Chaplin, CEO of Kardium
“We are delighted to join Kardium as an investor. The Globe System is a disruptive innovation with exemplary clinical outcomes that has the potential to improve the lives of patients with atrial fibrillation. This is a pivotal moment in the evolution of AF treatment, as the field transitions toward pulsed field ablation, and we are proud to help support the introduction of Kardium’s groundbreaking technology to the market.”
Aaron Schaechterle, Portfolio Manager at Janus Henderson Investors
